To include your compound in the COVID-19 Resource Center, submit it here.

REG1 Anticoagulation System: Phase IIb data

The double-blind reversal, active-controlled, international Phase IIb RADAR trial in 640 evaluable ACS patients undergoing cardiac catheterization showed that Regado's REG1 Anticoagulation System met 1 of 2 co-primary endpoints. On the first co-primary endpoint, the arm consisting of 100%

Read the full 394 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE